Fact based stock research
Fresenius (XTRA:FRE)

DE0005785604

Fresenius stock research in summary

fresenius.com


Fresenius shares are less expensive than other comparable stocks. While they are good value, they are riskily financed, and show below average growth. We recommend evaluating whether the future of the company Fresenius is really as difficult as the low price of the stock suggests. If you believe that the future of the company is market-typical or even better, then this could be an argument for a share purchase.


Latest Obermatt Ranks


Country Germany
Industry Health Care Services
Index CDAX, DAX 40
Size class XX-Large

June 2, 2022. Stock data may be delayed. Login to get the most recent research.



Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Fresenius from June 2, 2022.

We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.